Alcobra Ltd. (ADHD) belonging to the Medical sector has surged 1.67% and closed its last trading session at $1.22.
The company reported its EPS on 02/15/2017. Currently, the stock has a 1 Year Price Target of $1.94.
The consensus recommendation, according to Zacks Investment research, is 3. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 3 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.75 and 2.75 respectively.
Alcobra Ltd. on 02/15/2017 reported its EPS as $-0.22 with the analysts projecting the EPS of the stock as $-0.27. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 18.5%.
Many analysts have provided their estimated foresights on Alcobra Ltd. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.17.
Whereas they predicted High and Low Earnings Estimate as $-0.14 and $-0.25 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.18.
For the Current Quarter, the growth estimate for Alcobra Ltd. is 5.6%, while for the Next Quarter the stock growth estimate is 19%.
The Company got Downgrade by Jefferies on 18-Jan-17 from Buy to Hold.
6 analysts projected Price Targets for Alcobra Ltd.. The analysts believe that the company stock price could grow as high as $4. The Low Price target projection by analysts is $1 and the Mean Price Target is $1.94.
Alcobra Ltd. (ADHD) has the market capitalization of $33.94 Million. The company rocked its 52-Week High of $5.75 on Jun 1, 2016 and touched its 52-Week Low of $0.83 on Jan 17, 2017.
The stock has Return on Assets (ROA) of -36.6 percent. Return on Equity (ROE) stands at -38.2% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -41.9 Percent. The company has Beta Value of 1.47 and ATR value of 0.08. The Weekly and Monthly Volatility stands at 5.29% and 6.84%.